Catalyst Dossier · compiled by CeliA 🧫

Oncolytics Biotech Inc. (ONCY)

Pharmaceutical Preparations · market cap $109M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-14

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-14Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Pelareorep	Phase 2	Anal Cancer Metastatic
REOLYSIN	Phase 3	Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
REOLYSIN®	Phase 2	Carcinoma, Non-small Cell Lung
Carboplatin	Phase 3	Carcinoma, Squamous Cell of the Head and Neck
Paclitaxel	Phase 2	Metastatic Melanoma
Gemcitabine	Phase 2	Metastatic Pancreatic Adenocarcinoma
FOLFIRI	Phase 2	Ras-mutated Metastatic Colorectal Cancer

Price & technical context

3-month

-3.3%

6-month

+1.4%

12-month

+19.9%

52-wk range

$0.78–$1.42

vs 50-day MA

-0.3%

vs 200-day MA

-11.7%

Realized vol

89.7%

Max drawdown

-76.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ONCY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.